High-Dose Medroxyprogesterone Acetate in Advanced Melanoma
Author Information
Author(s): R. Becher, 0. Kloke, K. Hoffken, M.E. Scheulen, U.B. Wandl, H. Bojar, C.G. Schmidt
Primary Institution: Westdeutsches Tumorzentrum
Hypothesis
The study aims to assess the therapeutic relevance of high glucocorticoid receptor levels in advanced malignant melanoma using high-dose medroxyprogesterone acetate.
Conclusion
High-dose medroxyprogesterone acetate has little or no tumor-reductive effect in advanced malignant melanoma.
Supporting Evidence
- All patients received 1 g MPA per day as intramuscular injection on days 1-10.
- Two patients had disease stabilization for 3 months.
- Weight gain of more than 3 kg was observed in three patients.
Takeaway
Doctors tried a strong medicine to help people with a serious skin cancer, but it didn't really work.
Methodology
Eighteen outpatients with advanced malignant melanoma were treated with high-dose medroxyprogesterone acetate and evaluated for response.
Limitations
The study had a small sample size and no objective responses were observed.
Participant Demographics
Median age was 45 years, with a range from 12 to 72 years.
Statistical Information
Confidence Interval
95%
Want to read the original?
Access the complete publication on the publisher's website